Alembic Pharmaceuticals reported its financial results for Q2 FY25, showing positive year-over-year (YoY) growth in both revenue and net profit, though quarter-over-quarter (QoQ) figures reflected modest changes.
Financial Highlights
- Revenue: Alembic’s revenue from operations for Q2 FY25 rose to ₹1,647.98 crore, marking a 3.3% YoY increase from ₹1,594.93 crore in Q2 FY24. On a QoQ basis, revenue showed a slight increase of 5.5% from ₹1,561.73 crore in Q1 FY25.
- Net Profit (PAT): The company’s net profit for Q2 FY25 stood at ₹153.41 crore, up 12.2% YoY from ₹136.56 crore in the same quarter last year. QoQ, net profit increased by 13.9% from ₹134.71 crore in Q1 FY25.
Alembic Pharma’s YoY growth in revenue and profit reflects solid performance, attributed to increased sales and cost management. However, the relatively modest QoQ improvements indicate the need for sustained growth to keep up the momentum.
TOPICS:
Alembic Pharma